Table 4.
Comparison of Dose Delivery in the CA031 Study and the Present Study.
| Subgroup | Cycles | nab-paclitaxel | carboplatin | ||
|---|---|---|---|---|---|
| Cumulative dose (mg/m2) |
Dose intensity (mg/m2/week) |
Cumulative dose (mg/m2) |
Dose intensity (mg/m2/week) |
||
| Patients without preexisting ILD (The CA031 study) | |||||
| NSCLC [3] | 6 | 1,325 | 82 | 3,140 | 166 |
| Lung SCC [4] | 6 | 1,475 | 85.2 | N/A | N/A |
| Elderly NSCLC [20] | 5 | 1,150 | 73.4 | 2,428 | 127.7 |
| Patients with preexisting ILD (The present study) | |||||
| Elderly lung SCC | 4 | 850 | 62 | 1,712 | 71 |
nab-paclitaxel: nanoparticle albumin-bound-paclitaxel, ILD: interstitial lung disease, NSCLC: non-small cell lung cancer, SCC: squamous cell carcinoma, N/A: not available